메뉴 건너뛰기




Volumn 38, Issue 11, 2015, Pages 595-599

Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation

Author keywords

Anticoagulants; Extracorporeal membrane oxygenation; Nafamostat

Indexed keywords

BLOOD; OXYGENATION;

EID: 84953730318     PISSN: 03913988     EISSN: 17246040     Source Type: Journal    
DOI: 10.5301/ijao.5000451     Document Type: Article
Times cited : (22)

References (14)
  • 1
    • 84903158141 scopus 로고    scopus 로고
    • Extracorporeal membrane oxygenation in cardiopulmonary disease in adults
    • Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63(25):2769-2778.
    • (2014) J am Coll Cardiol , vol.63 , Issue.25 , pp. 2769-2778
    • Abrams, D.1    Combes, A.2    Brodie, D.3
  • 2
    • 67650391955 scopus 로고    scopus 로고
    • And the winner is: Regional citrate anticoagulation
    • Bouman CS. And the winner is: regional citrate anticoagulation. Crit Care Med. 2009;37(2):764-765.
    • (2009) Crit Care Med , vol.37 , Issue.2 , pp. 764-765
    • Bouman, C.S.1
  • 3
    • 0021265581 scopus 로고
    • Pharmacological studies of FUT- 175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments
    • Aoyama T, I no Y, Ozeki M, et al. Pharmacological studies of FUT- 175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35(3): 203-227.
    • (1984) Jpn J Pharmacol , vol.35 , Issue.3 , pp. 203-227
    • Aoyama, T.1    No, Y.2    Ozeki, M.3
  • 4
    • 0022177378 scopus 로고
    • Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175
    • Miyamoto Y, Hirose H, Matsuda H, et al. Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175. Trans Am Soc Artif Intern Organs. 1985;31:508-511.
    • (1985) Trans am Soc Artif Intern Organs , vol.31 , pp. 508-511
    • Miyamoto, Y.1    Hirose, H.2    Matsuda, H.3
  • 5
    • 84907847994 scopus 로고    scopus 로고
    • Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One. 2014;9(10):e108737.
    • Lee, Y.K.1    Lee, H.W.2    Choi, K.H.3    Kim, B.S.4
  • 6
    • 84863239727 scopus 로고    scopus 로고
    • The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding
    • Baek NN, Jang HR, Huh W, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34(3):279-285.
    • (2012) Ren Fail , vol.34 , Issue.3 , pp. 279-285
    • Baek, N.N.1    Jang, H.R.2    Huh, W.3
  • 7
    • 79961087823 scopus 로고    scopus 로고
    • Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: A three-year retrospective cohort study
    • Maruyama Y, Yoshida H, Uchino S, et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs. 2011;34(7):571-576.
    • (2011) Int J Artif Organs , vol.34 , Issue.7 , pp. 571-576
    • Maruyama, Y.1    Yoshida, H.2    Uchino, S.3
  • 8
    • 84891428990 scopus 로고    scopus 로고
    • Nafamostat mesilate: Can it be used as a conduit preserving agent in coronary artery bypass surgery
    • Yoon YS, Oh H, Kim Y, Lim SP, Kim CS, Kang MW. Nafamostat mesilate: can it be used as a conduit preserving agent in coronary artery bypass surgery? Korean J Thorac Cardiovasc Surg. 2013;46(6):413-425.
    • (2013) Korean J Thorac Cardiovasc Surg , vol.46 , Issue.6 , pp. 413-425
    • Yoon, Y.S.1    Oh, H.2    Kim, Y.3    Lim, S.P.4    Kim, C.S.5    Kang, M.W.6
  • 9
    • 79960148135 scopus 로고    scopus 로고
    • Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation
    • Han SJ, Kim HS, Kim KI, et al. Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. J Korean Med Sci. 2011;26(7):945-950.
    • (2011) J Korean Med Sci , vol.26 , Issue.7 , pp. 945-950
    • Han, S.J.1    Kim, H.S.2    Kim, K.I.3
  • 10
    • 0030953579 scopus 로고    scopus 로고
    • Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygen- ation—a preliminary report
    • Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygen- ation—a preliminary report. J Pediatr Surg. 1997;32(4):531-535.
    • (1997) J Pediatr Surg , vol.32 , Issue.4 , pp. 531-535
    • Nagaya, M.1    Futamura, M.2    Kato, J.3    Niimi, N.4    Fukuta, S.5
  • 11
    • 0035109624 scopus 로고    scopus 로고
    • Extracorporeal membrane oxygenation for newborns with gastric rupture
    • Nagaya M, Kato J, Niimi N, Tanaka S. Extracorporeal membrane oxygenation for newborns with gastric rupture. Pediatr Surg Int. 2001;17(1):35-38.
    • (2001) Pediatr Surg Int , vol.17 , Issue.1 , pp. 35-38
    • Nagaya, M.1    Kato, J.2    Niimi, N.3    Tanaka, S.4
  • 12
    • 0019817468 scopus 로고
    • New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin
    • Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981;661(2):342-345.
    • (1981) Biochim Biophys Acta , vol.661 , Issue.2 , pp. 342-345
    • Fujii, S.1    Hitomi, Y.2
  • 13
    • 0029614808 scopus 로고
    • Mechanisms of hyperkalemia caused by nafamostat mesilate
    • Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. Gen Pharmacol. 1995;26(8):1627-1632.
    • (1995) Gen Pharmacol , vol.26 , Issue.8 , pp. 1627-1632
    • Muto, S.1    Imai, M.2    Asano, Y.3
  • 14
    • 0028950164 scopus 로고
    • Hyperkalemia due to nafamostat mesylate
    • Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesylate. N Engl J Med. 1995;332(10):687.
    • (1995) N Engl J Med , vol.332 , Issue.10 , pp. 687
    • Kitagawa, H.1    Chang, H.2    Fujita, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.